Adamis Pharma to Fund Clinical Study with University of Leiden Opioid Expert
By Chris Wack
Adamis Pharmaceuticals has committed to fund an unrestricted research grant to the Leiden University Medical Center Anesthesia and Pain Research Unit.
The funding will support the work of Albert Dahan, a world expert on opioid-induced respiratory depression and professor of anesthesiology at the university.
Dahan has been working with the FDA since 2020 to understand better methods of reversing fentanyl overdoses.
Dahan said that the objective of this collaboration will be to assess the efficacy of 5mg intramuscular ZIMHI versus 4mg of intranasal naloxone, which is comparable to Narcan and the respective number of doses required to reverse fentanyl-induced respiratory depression.
Adamis shares were up 5% to $1.72 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 28, 2023 09:03 ET (13:03 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing